Background
The I-MOVE (Influenza – Monitoring Vaccine Effectiveness in Europe) network aims to measure influenza vaccine effectiveness (VE) in Europe. The project started in 2007 and has carried out multicentre and other studies since the 2008–9 influenza season.
The network consists of 29 partners including ECDC, WHO-EURO, regional and national public health institutes, hospitals, small and medium enterprises, and universities from 15 European Union/European Economic Area Member States. The I-MOVE network measures VE in a way that is scientifically and financially independent from vaccine manufacturers.
The I-MOVE network includes a multicentre study at primary care level to measure influenza VE and a multicentre study carried out at hospital level to measure VE against severe influenza. Within the I-MOVE network we also carry out studies measuring the impact of influenza vaccination campaigns.
partners
Partners taking part in I-MOVE multicentre studies
- Public health Institute Albania
- CNIPH Croatia
- Public Health England
- Centre Hospitalier Universitaire, Montpellier, France
- Université Sorbonne, France
- Institut Pasteur, France
- Université de Corse Pascal Paoli, France
- RKI, Germany
- Vienna Vaccine Safety Initiative (ViVI), Germany
- HPSC, Ireland
- Lithuanian University of Health Sciences, Lithuania
- RIVM, The Netherlands
- NIVEL, The Netherlands
- INS Ricardo Jorge, Portugal
- INCDMIC Cantacuzino, Romania
- Healh Protection Scotland
- ISCIII, Spain
- ISPL-Navarra, Spain
- Public Health Agency, Sweden
- Epiconcept, France (I-MOVE coordination)
Other partners
- SSI, Denmark
- RCGP, England
- THL, Finland
- Assistance Publique Hôpitaux de Paris, France
- Centre Hospitalier Universitaire, Rennes, France
- Hospices Civiles de Lyon – Hôpital Edouard Herriot, France
- Hospices Civiles de Lyon – Hôpital de la Croix Rouge, France
- Santé Publique France
- I-REIVAC and CC Cochin, France
- ISS, Italy
- NIPH, Norway
- NIZP-PZH, Poland
Funding
The I-MOVE network has received funding from the European Centre for Disease Prevention and Control (ECDC)(primary care network: ECDC/2018/029), WHO-EURO (hospital network), the European Commission (from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 634446), Epiconcept and Member States.
